Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which works by mimicking the action of the natural hormone GLP-1. GLP-1 is involved in glucose regulation and has several beneficial effects, including:
The rise of GLP-1 receptor agonists, specifically Semaglutide (Ozempic), for the treatment of Type 2 Diabetes and obesity has led to a global surge in demand. Concurrently, a practice known as "click counting" or "dial dosing" has emerged within patient communities. This practice involves using the mechanical clicking mechanism of the Ozempic pen to administer doses smaller than the officially calibrated markings, or to extend the supply of medication. This paper explores the technical feasibility, pharmacological rationale, prevalence, and safety concerns surrounding click counting, highlighting the risks of dosing inaccuracy and the tension between patient autonomy and manufacturer guidelines. ozempic click dosing
Let’s be clear upfront: The pens are designed for fixed doses. However, in the real world of shortage-driven supply chains, high drug prices, and sensitive human biology, click dosing has become a lifeline. However, in the real world of shortage-driven supply
While the logic of mechanical division appears sound to patients, clinicians and the manufacturer cite significant safety risks: high drug prices